Windlas Biotech Ltd

WINDLAS

Watchlist

AI Mode

‌

Market Cap

₹ 1,623 Cr

P/E

24.11

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

MODERATE MARGIN

Technicals

Bearish

Risk

MODERATE RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Windlas Biotech Limited is a leading pharmaceutical company specializing in generic formulations, trade generics, and CDMO services. With robust 19% YoY revenue growth reported, the company showcases strong operational performance and strategic execution across its core verticals.

The expansion of Plant-2 and ongoing Plant-6 developments signify its commitment to enhancing production capabilities, targeting long-term growth. Notably, the company's diversified revenue streams span top-tier pharmaceutical partnerships across its business verticals.

Windlas Biotech maintains a sophisticated R&D infrastructure that propels innovation in complex generic product development, showcasing its aptitude for advanced pharmaceutical solutions.

A proactive ESOP scheme aligns corporate goals with talent retention, rewarding 100 employees to sustain growth momentum and operational excellence.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

1,623 Cr

Volatility

High Risk

P/E Ratio

24.1

Industry P/E

43.5

PEG Ratio

1.4

P/B Ratio

3.0

52W High

1,137.60

52W Low

667.30

Sales CAGR

20.43%

17.71%

18.24%

10Y

—

Profit CAGR

4.81%

16.99%

30.34%

10Y

—

ROE

TTM

12.60%

11.88%

10.50%

10Y

11.16%

ROCE

TTM

16.43%

15.99%

14.17%

10Y

14.06%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AMRUTANJAN	680.00	1,967 Cr	34.69	5.75	0.68	16.57	22.53	13.11
WINDLAS	776.00	1,623 Cr	24.11	3.04	0.75	12.60	16.43	8.27
BLISSGVS	143.80	1,520 Cr	13.87	1.34	0.35	9.68	14.69	8.24
SYNCOMF	14.82	1,395 Cr	22.15	3.69	0.00	16.66	22.00	13.82
HESTERBIO	1593.00	1,343 Cr	30.63	3.97	0.44	12.98	9.93	6.60
LINCOLN	485.55	975 Cr	12.18	1.36	0.37	11.18	15.34	9.36
FREDUN	1743.40	823 Cr	22.91	5.23	0.04	22.85	26.16	7.74

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	145	153	162	171	175	187	195	203	210	222
Expenses	128	134	142	149	154	164	170	177	184	194
Operating Profit	17	19	20	22	21	23	25	26	27	29
OPM %	11.84	12.24	12.53	12.85	11.92	12.33	12.63	12.61	12.63	12.84
Other Income	2.62	3.24	3.16	4.44	4.13	4.84	4.11	4.94	5.24	3.65
Interest	0.24	0.29	0.31	0.28	0.49	1.10	1.46	1.33	1.06	1.02
Depreciation	3.19	3.33	3.39	3.54	6.21	6.50	6.94	8.34	7.45	7.60
Profit Before Tax	16	18	20	23	18	20	20	21	23	24
Tax %	26.19	23.38	23.78	24.92	26.38	22.82	23.40	21.81	24.03	24.54
Net Profit	12	14	15	17	13	16	16	16	18	18
EPS in Rs	5.71	6.66	7.16	8.06	6.42	7.43	7.32	7.65	8.29	8.40

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	352	307	329	428	466	513	631	760	795
Expenses	313	269	287	373	414	453	553	666	695
Operating Profit	39	39	41	55	52	60	78	94	100
OPM %	11.21	12.53	12.61	12.79	11.25	11.74	12.39	12.38	12.55
Other Income	4.33	53	-4.98	-19	6.71	9.97	13	18	19
Interest	6.47	4.84	2.53	1.29	1.42	0.79	1.11	4.38	4.95
Depreciation	17	11	9.29	13	12	12	13	28	29
Profit Before Tax	20	76	25	22	46	57	77	80	85
Tax %	43.59	16.15	34.28	28.38	16.41	25.27	24.52	23.53	23.06
Net Profit	11	64	16	16	38	43	58	61	65
EPS in Rs	—	—	—	8.70	19.13	20.08	27.60	28.81	31.66
Dividend Payout %	0.00	0.00	0.00	0.00	18.84	20.30	19.73	20.09	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	5.59	6.41	6.41	6.41	11	10	10	10
Reserves	119	187	203	193	384	392	440	495
Borrowings	44	25	24	32	6.64	4.99	3.64	33
Other Liabilities	120	80	105	65	90	122	173	222
Total Liabilities	290	298	338	296	491	529	626	760
Fixed Assets	86	64	70	96	91	109	179	223
CWIP	53	4.58	0.00	0.04	8.01	15	5.71	5.32
Investments	23	122	116	23	65	107	173	223
Other Assets	128	107	152	177	327	298	268	308
Total Assets	290	298	338	296	491	529	626	760

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	35	19	25	11	9.13	61	109	68
Cash from Investing Activity	-11	-6.77	-14	-20	-155	-14	-92	-74
Cash from Financing Activity	-26	-6.23	-5.44	0.78	130	-44	-15	1.01
Net Cash Flow	-2.16	5.66	5.22	-7.97	-15	3.12	1.60	-4.86

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Apr 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	62.44%	62.44%	62.82%	62.82%	62.82%	62.82%	62.51%	62.51%	62.51%	62.34%	62.34%	61.99%
FIIs	1.24%	1.24%	0.80%	0.80%	1.35%	1.18%	1.59%	2.00%	1.55%	1.52%	1.44%	1.11%
DIIs	11.64%	11.64%	11.53%	11.53%	11.71%	11.82%	10.35%	9.58%	10.26%	10.89%	11.21%	11.43%
Public	24.68%	24.68%	24.85%	24.85%	24.12%	24.19%	25.55%	25.91%	25.68%	25.25%	25.01%	25.47%
Total Shareholders	78,829	78,829	75,470	68,798	61,900	51,277	45,824	45,706	46,590	46,383	45,887	45,433

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Feb 20, 2025	Ajay kumar aggarwal	Bulk	Buy	787.42	11.42 Cr	1,44,995	0.69
Feb 19, 2025	Samvitti capital private limi...	Bulk	Sell	683.49	7.89 Cr	1,15,374	0.55
Jan 02, 2024	Jainam broking limited	Bulk	Sell	520.70	5.01 Cr	96,128	0.45
Jan 02, 2024	Jainam broking limited	Bulk	Buy	511.50	7.67 Cr	1,50,028	0.71

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q4 FY24

Investor Presentation

Q3 FY24

Investor Presentation

Q2 FY24

Showing 1 - 8 of 18

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Overview

Detailed Summary

Windlas Biotech maintains a sophisticated R&D infrastructure that propels innovation in complex generic product development, showcasing its aptitude for advanced pharmaceutical solutions.

A proactive ESOP scheme aligns corporate goals with talent retention, rewarding 100 employees to sustain growth momentum and operational excellence.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Formulations

Market Cap

1,623 Cr

Volatility

High Risk

P/E Ratio

24.1

Industry P/E

43.5

PEG Ratio

1.4

P/B Ratio

3.0

52W High

1,137.60

52W Low

667.30

Sales CAGR

20.43%

17.71%

18.24%

10Y

—

Profit CAGR

4.81%

16.99%

30.34%

10Y

—

ROE

TTM

12.60%

11.88%

10.50%

10Y

11.16%

ROCE

TTM

16.43%

15.99%

14.17%

10Y

14.06%

Windlas

Windlas Biotech Ltd

WINDLAS

AI Mode

Investment Checklist

Investment Checklist

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Technicals

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Projection

Actions

Announcements

Documents

AI Mode

AI Mode

Forecasts

Projection

Windlas Biotech Ltd

WINDLAS

AI Mode

Peers

Price Chart Comparison

Announcements

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Investment Checklist